Each film coated tablet contains Flupentixol 0.5 mg as Flupentixol Hydrochloride BP and Melitracen 10 mg as Melitracen Hydrochloride INN.
Melixol® tablet contains two active ingredients. Among of these two active ingredients, Flupentixol primarily acts as a neuroleptic drug. The antipsychotic effect of Flupenthixol is achieved by mixed blockade of dopamine D₁ and D₂ receptors. In the mesolimbic dopamine system of the brain, this accounts for the antipsychotic action of this drug. Flupentixol has other effects on CNS. In the chemoreceptor trigger zone, the dopamine blockade accounts for the antiemetic effect of the drug. Melitracen is a tricyclic antidepressant. It blocks the neuronal re-uptake of both serotonin and nor-epinephrine in the central nervous system, thereby minimizing the symptoms of depression.
Melixol® is indicated in anxiety along with depression and apathy. These includes:
Adults: In general 2 tablets per day, morning and at midday. For the severe cases, the amount of the morning dose can be increased to 2 tablets. Elderly patients: One tablet in the morning.
Maintenance dose: 1 tablet in the morning. In cases of insomnia or severe restlessness additional treatment with a sedative in acute phase is recommended.
Children: This tablet is not for paediatric use.
This tablet should preferably not be given during pregnancy and lactation.
The administration of this requires prudence among patients presenting an organic cerebral lesion, convulsions, urinary retention, hyperthyroid, parkinson’s syndrome, serious myasthenia, advanced hepatic affection as well as cardiovascular disorders. Because it has a stimulating effect, this is not recommended at the agitated patients.
Among depressive patients, the risk of suicide remains during the treatment, until the appearance of a marked remission of the depressive symptoms. During the treatment, the patients having a tendency to suicide should not have access to the drug in great quantities. As for the other psychotropic ones, this combination tablet can deteriorate the tolerance with glucose and insulin. An antidiabetic adaptation of the treatment can prove to be necessary. Because it dilates the pupil, this tablet can cause an acute crisis of glaucoma among patients having glaucoma at closed angle or a narrowness of the irido-corneal angle.
The administration of anaesthetic buildings during a treatment by tricyclic or tetracyclic antidepressants can increase the risk of arrhythmias and hypotension. If possible a treatment by this tablet may be stopped a few days before an operation envisaged. One should inform the anaesthetist in the emergency cases where the treatment cannot be stopped in advance.
As for all nerve sedatives, a syndrome nerve sedative (potentially fatal) can seldom occur. Extrapyramidal disorders can occur in very rare cases, mainly at the beginning of a treatment by Flupenthixol. Potentially irreversible late dyskinesis are possible during one long-term treatment with nerve sedatives like the Flupentixol. To regularly control the psychological and neurological situation, the blood picture and the hepatic function of the patients under long-term treatment by Flupentixol should be monitored.
Store below 25°C, protected from light and moisture. Keep medicine out of the reach of children.